The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Median nerve electrical stimulation treatment, Huperzine A injection, Ginkgo leaf dropping pill.
- Who it may be relevant to
- Registry conditions: Cognitive Impairment After Brain Injury. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study will conduct a single-center clinical trial to explore the initial therapeutic effect of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment.
Detailed description
Specific experimental research methods were randomized, controlled, single-center, exploratory clinical study, through the treatment of ginkgo biloba dropping pills, huperzine A injection and median nerve electrical stimulation in patients with cognitive impairment, to observe the effects of their neuroprotection and cognitive function improvement.
Interventions
- Other Median nerve electrical stimulation treatment
Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of - Drug Huperzine A injection
intramuscular - Drug Ginkgo leaf dropping pill
oral
Primary outcome measures
- to assess the MMSE score [Time frame: baseline，Day10，Day90]
Secondary outcome measures (4)
- to assess the MoCA score [Time frame: baseline，Day10，Day90]
- to assess the ADAS-cog score [Time frame: baseline，Day10，Day90]
- to assess the HAMD score [Time frame: baseline，Day10，Day90]
- to assess the HAMA score [Time frame: baseline，Day10，Day90]
Eligibility criteria
Inclusion criteria
- Be over 18 years old
- Residual cognitive impairment due to brain injury
- No previous history of brain-related diseases except this one
Exclusion criteria
- The patient had severe underlying disease and unstable vital signs
- The patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment ③ Allergic to drugs or contraindications in drug use ④ There are contraindications of median nerve electrical stimulation
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- The Ganzhou City People's Hospital — Ganzhou
Identifiers
NCT: NCT06704334 · 2024-03-06